medigraphic.com

2008, Number 1

<< Back Next >>

Arch Cardiol Mex 2008; 78 (1)

High and low density lipoprotein abnormalities in coronary patients with LDL-C at target and uncontrolled HDL-C and triglycerides

Posadas-Romero C, Posadas-Sánchez R, Juárez-Rojas JG, Medina-Urrutia A, Jorge-Galarza E, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Pérez E

Language: Spanish
References: 47
Page: 30-39
PDF size: 148.50 Kb.


ABSTRACT

Objective: To investigate the high density lipoprotein (HDL) subclasses distribution and chemical composition, as well as low density lipoprotein (LDL) size and LDL oxidation, in coronary male patients treated with statins, that had LDL-cholesterol levels at target (‹ 100 mg/dL), but whose HDL-cholesterol (‹ 40 mg/dL) and triglycerides (TG ³ 150 mg/dL) levels were abnormal. The control group was formed by statin treated coronary male patients with LDL-C below 100 mg/dL and normal HDL-C and TG levels. Material and methods: HDL subclasses and LDL size were determined by gradient gel electrophoresis. LDL susceptibility to oxidation was determined by measuring lag phase duration, after adding the oxidant agent. Results:<|b> Compared with the control group (n = 35), patients with low HDL-C + high TG (n = 34) showed significantly lower proportions of large HDL and higher proportions of small HDL particles. In addition, these patients had abnormal HDL composition, smaller LDL size, and higher LDL susceptibility to oxidation (p ‹ 0.05 for all). Conclusions: Coronary patients with optimal LDL-C levels on statin therapy but with low HDL-C and high TG, have HDL and LDL abnormalities that have been shown to be associated with a higher risk of new coronary events.


REFERENCES

  1. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.

  2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med 2004; 350: 1495-1504.

  3. La Rosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al: Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.

  4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.

  5. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.

  6. Williams PT, Krauss RM, Nichols AV, Vranizan KM, Wood PD: Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 1990; 31: 1131-1139.

  7. von Eckardstein A, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5: 404-416.

  8. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888.

  9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.

  10. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-2191.

  11. Kontush A, de Faria EC, Chantepie S, Chapman MJ: A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182: 277-285.

  12. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-4971.

  13. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G: Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 656-661.

  14. Brites FD, Bonavita CD, De Geitere C, Cloes M, Delfly B, Yael MJ, et al: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000; 152: 181-192.

  15. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-369.

  16. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.

  17. Barter P, Gotto A, La Rosa J, Grundy S, Kastelein J, Bittner V, et al: On-treatment levels of HDL-C and the ratio of LDL-C/HDL-C as predictors of cardiovascular events in the treating to new targets (TNT) study. ACC 55th Annual Scientific 2006 (Abstract): 914-203.

  18. Barengo NC, Hu G, Lakka TA, Pekkarinen H, Nissinen A, Tuomilehto J: Low physical activity as a predictor for total and cardiovascular disease mortality in middle-aged men and women in Finland. Eur Heart J 2004; 25: 2204-2211.

  19. Andersen LB, Schnohr P, Schroll M, Hein HO: All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Arch Intern Med 2000; 160: 1621-1628.

  20. Sánchez-Castillo CP, Velázquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP: Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003; 11: 442-451.

  21. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al: Direct measurement of High-Density lipoprotein cholesterol in serum with polyethylene gycol-modified enzymes and sufated a-cyclodextrin. Clin Chem 1995; 41: 717-723.

  22. De Long D, De Long E, Wood P, Lippel K, Rifkind BM: A comparison of methods for the estimation of plasma low- and very low- density lipoprotein cholesterol. JAMA 1986; 256: 2372-2377.

  23. Tailleux A, Torpier G, Caron B, Fruchart JC, Fievet C: Immunological properties of apo B- containing lipoprotein particles in human atherosclerotic arteries. J Lipid Res 1993; 34: 719-728.

  24. Blanche P, Gong E, Forte T, Nichols AV: Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419.

  25. Perusse M, Pascot A, Despres JP, Couillard C, Lamarche B: A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001; 42: 1331-1334.

  26. Laemmli U: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.

  27. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.

  28. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67-75.

  29. Godsland IF, Crook D, Walton C, Wynn V, Oliver MF: Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb 1992; 12: 1030-1035.

  30. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462.

  31. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, et al: Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.

  32. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.

  33. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, et al: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-2676.

  34. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al: High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187.

  35. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR: Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hipercolesterolemia. J Lab Clin Med 1989; 114: 250-259.

  36. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995; 114: 223-234.

  37. Asztalos BF, MCTaggarr F, Horvath KV, Lemaulf F, Dallal GE, Schaefer EJ: Effect of maximal statin therapy on the high density lipoprotein (HDL) subpopulation profiles of hypercholesterolemic subjects. (Abstract). Atherosclerosis supplements 2006; 7: 580.

  38. Assmann G, Nofer JR: Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341.

  39. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR: High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274: 33143-33147.

  40. Barter PJ, Baker PW, Rye KA: Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13: 285-288.

  41. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1450-1455.

  42. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69-75.

  43. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-888.

  44. Dejager S, Bruckert E, Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308.

  45. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.

  46. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT: The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: 34C-39C.

  47. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23: 847-852.




2020     |     www.medigraphic.com